EndoPredict is the only second generation breast cancer prognostic test validated for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive1,3-8 – and the first second generation test with level of evidence 1A data.9,10
EndoPredict is the only test to provide recurrence risk data for 5-15 years1, giving additional peace-of-mind for patient safety and helping clinicians decide if long-term adjuvant endocrine therapy can be avoided.
If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.
What is the risk of breast cancer relapsing after treatment?
Breast cancer recurrence risk continues beyond 5 years of endocrine therapy. More than 50% of late recurrences in women with ER positive/HER2 negative disease occur after 5 years’ endocrine treatment.11
Accurate long-term prognosis is therefore crucial to help clinicians to decide if stopping hormone therapy with their breast cancer patient is the right decision.
EndoPredict is the only prognostic test that accurately predicts late recurrence risk in breast cancer patients, regardless of positive lymph nodes and even for women distant recurrence-free at 5 years1 – for decisions going beyond adjuvant chemotherapy.
This study assessed the ability of EPclin to predict early and late recurrence in 1,072 postmenopausal women with early-stage ER positive/HER2 negative breast cancer enrolled in the randomized phase III ABCSG-6 and ABCSG-8 trials using a follow-up of up to 15 years:
The EPclin Risk Score combines clinical and molecular factors for enhanced prognostic performance, supporting accurate decisions.4
The 12-Gene Molecular Score monitors for genes selected to optimize prediction of early and late recurrence (0-15 years) – this is why EndoPredict provides the most accurate long-term recurrence risk for breast cancer.1,8
The EndoPredict animated app can show you how various gene activities in the tumor influence the prognosis and how the molecular fingerprint and tumor size and nodal status contribute to the final EndoPredict result.
EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.